Debevoise & Plimpton LLP
Fried, Frank, Harris, Shriver & Jacobson LLP
Mark is an accomplished and versatile corporate and transactional attorney with over 30 years’ legal experience focused mostly on advising clients in the life sciences industry. Mark regularly represents companies in structuring, drafting and negotiating strategic transactions at all stages of the product lifecycle - from research and development through commercialization - frequently involving cutting-edge technologies, including RNAi, cell therapy, gene therapy, multi-specifics antibodies and CRISPR, as well as devices, device-drug combinations and diagnostics.
Mark understands that every deal is different, often posing bespoke challenges that reflect an evolving scientific, intellectual property, regulatory and business landscape. His knowledge combined with broad transactional experience, including in-house within large pharma, finance and M&A, enables him to translate complex scientific and IP concepts into practical business solutions for his clients.
Mark began his career as an attorney at a top tier international law firm in New York focusing on M&A, securities law and structured finance transactions. He then spent over 17 years in-house at Pfizer, where he handled several high profile business transactions; advised C-suite executives and senior leadership teams for Pfizer’s R&D organization; and led a team of attorneys focused on sophisticated and complex life sciences transactions for over a decade.
Mark teaches the contracting section for the Business Development course at BIO’s annual international convention and is a frequent panelist at other industry meetings and seminars.
Vice President and Assistant General Counsel
A representative list of Mark’s transactional matters at Pfizer include: